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Aberrant activation of telomerase occurs in 85–90% of all cancers and under-
pins the ability of cancer cells to bypass their proliferative limit, rendering
them immortal. The activity of telomerase is tightly controlled at multiple
levels, from transcriptional regulation of the telomerase components to
holoenzyme biogenesis and recruitment to the telomere, and finally acti-
vation and processivity. However, studies using cancer cell lines and other
model systems have begun to reveal features of telomeres and telomerase
that are unique to cancer. This review summarizes our current knowledge
on the mechanisms of telomerase recruitment and activation using insights
from studies in mammals and budding and fission yeasts. Finally, we dis-
cuss the differences in telomere homeostasis between normal cells and
cancer cells, which may provide a foundation for telomere/telomerase
targeted cancer treatments.1. Introduction: chromosome maintenance and cell
proliferation
1.1. Telomere homeostasis in normal and cancer cells
All dividing eukaryotic cells require telomeres to maintain the ends of the
chromosomes and sustain chromosome stability. To protect the genetic
information contained within the chromosomes, telomeres sacrifice their non-
coding DNA sequences in the erosion that occurs during DNA replication in
each cell cycle [1,2]. Most somatic cells that have undergone sufficient cell div-
isions to cause critical telomere shortening enter into replicative senescence.
However, some cells, including lymphocytes, germ cells, stem cells and unicel-
lular eukaryotes like yeast, express the enzyme telomerase, which has the ability
to replenish telomeres and allow further replicative potential [3–7].
Telomerase is a ribonucleoprotein complex, composed of a reverse tran-
scriptase enzyme catalytic subunit and a long non-coding RNA that contains
the template sequence for telomere synthesis [6]. Whereas expression of the tel-
omerase components is tightly regulated in differentiated cells, the vast
majority of human cancers express active telomerase, effectively rendering
them immortal [8–10]. A direct correlation between telomere maintenance
and indefinite cell division was demonstrated in vitro by ectopic expression of
telomerase in somatic cell culture [11]. However, while cancer cells stably main-
tain telomeres, they tend to be short [12,13]. In particular, some of them are
critically short, termed ‘t-stumps’ [14], resulting in immortal cells that sustain
a high risk of chromosome instability. This is strikingly different from our
understanding of telomerase action in normal cells, in which telomerase prefer-
entially elongates shorter telomeres until they are no longer short [15–17]. Why
rsob.royalsocietypublishing.org
Open
Biol.7:160338
2
 on March 22, 2017http://rsob.royalsocietypublishing.org/Downloaded from telomerase acts differently in cancer cells remains a mystery.
In this review, we summarize our current knowledge of fun-
damental telomerase action, and highlight the phenotypes
uniquely observed in cancer cells.
1.2. Proliferation and protection: the problems faced by
telomeres
Progressive telomere shortening occurs each time a cell
divides owing to incomplete replication of linear chromo-
some ends by the conventional DNA polymerases. This
shortening is termed the end replication problem [18].
Nucleases also trim the telomeres to shape the chromosome
ends for protection, thereby causing loss of telomeric DNA
after S phase [19]. DNA replication-associated telomere
shortening limits the number of divisions a cell can undergo,
known as the Hayflick limit, before triggering the cessation of
growth [20]. Once telomeres become critically short, the DNA
damage response machinery is activated, and cells enter
replicative senescence or undergo programmed cell death
[21,22]. Telomere shortening leading to programmed cell
death is a major tumour suppressor mechanism, and as
such, most cancer cells require telomerase to be active in
order to survive.
In the absence of the senescence checkpoint per se, criti-
cally short telomeres become ‘uncapped’; they lose their
end protection ability. One essential role of the telomeres is
the differentiation of bona fide chromosomal ends from
damaged DNA double-stranded breaks [23,24]. This function
is indispensable for maintaining chromosome integrity, as
illicit repair of chromosome ends could result in chromosome
fusions. Such fusions would induce mitotic arrest and cell
death [25] or cause breakage–fusion–bridge cycles in sub-
sequent cell divisions, leading to translocations, aneuploidy
and eventually genomic instability [26]. This is called the
end protection problem.2. The structure of telomeres and
telomerase
2.1. The shelterin complex and telomere conformation
Telomeres are specialized DNA–protein complexes found at
the ends of all linear chromosomes. Telomeric DNA is com-
posed of arrays of short guanine-rich tandem repeats, and
while most of the telomere is double-stranded (ds), they ter-
minate in a single-stranded (ss) G-rich 30 overhang called the
G-tail [24,27–29]. These telomeric ds and ssDNA repeats are
covered by a specialized protein complex, termed shelterin, to
evade recognition of the chromosome ends by the DNA
damage response machinery. Together with the shelterin
complex, telomeres establish a heterochromatin structure
that packages up the ends of the chromosomes and prevents
them from being aberrantly recognized as DNA double-
stranded breaks (DSBs) [30]. The G-tail is thought not to be
exposed, but rather hidden within the dsDNA by forming a
displacement loop (D-loop). Telomeres are further compacted
into a lasso-like structure called a t-loop with the aid of the
proteins in the shelterin complex [31,32]. In addition, the shel-
terin complex interacts with DNA damage response factors,
preventing induction of their downstream pathways. Thus,failure of the chromosome ends to interact with shelterin
can expose the DNA ends and elicit the DNA damage
response [23,24,33].
In mammals, shelterin is composed of six proteins: TRF1,
TRF2, RAP1, TIN2, ACD (previously known as TPP1) and
POT1 (figure 1a) [34]. TRF1 and TRF2 bind the telomeric
dsDNA and recruit TIN2, which associates with ACD.
POT1 forms a heterodimer with ACD and directly binds to
the telomeric ssDNA at the D-loop and the G-tail. Thus,
the shelterin complex formation bridges the telomeric ds
and ssDNA and stabilizes the telomeric proteins. It is
also thought to negatively regulate telomere lengthening
[35–40]. TRF2 is required for the formation of t-loops
[31,32] and for suppressing ATM activation and non-
homologous end-joining (NHEJ) of chromosome ends [41].
These functions are promoted by TRF2-dependent topo-
logical changes [42]. RAP1, which binds to TRF2, is also
thought to play a role in inhibiting NHEJ and homology
directed repair but its actual function remains debatable
[43,44]. TRF2 and RAP1 may be redundantly required for
telomere protection even though RAP1 localization is depen-
dent on TRF2. Interestingly, TRF2 and RAP1 also bind to
internal telomere sequences and modulate transcription
[45]. TRF1 is dispensable for end protection, but is required
for lagging strand synthesis during DNA replication [46].
POT1 blocks the binding of replication protein A (RPA) to
the telomeric ssDNA, thereby preventing recruitment of
ATR [23]. Among the members of the shelterin complex,
TIN2 and ACD are responsible for recruiting telomerase to
the telomeres (discussed in a later section).
The shelterin complex is well conserved between fission
yeast and mammals (figure 1b) [34,47,48]. The telomeric
dsDNA binding protein Taz1 (orthologue of TRF1 and
TRF2 in mammals) supports the replication of telomeric
DNA and inhibits the NHEJ pathway [49,50]. Pot1 directly
binds the telomeric ssDNA to inhibit degradation of chromo-
some ends [51]. Like mammalian shelterin, Taz1 forms the
shelterin bridging structure with Rap1, Poz1 (TIN2 ortholo-
gue), Tpz1 (ACD orthologue) and Pot1 [48]. Thus, fission
yeast shelterin also connects the ds and ss telomeric DNA,
and maintenance of this connection has been shown to nega-
tively regulate telomerase activity [48,52–55]. Tpz1 also
interacts with Ccq1, which recruits telomerase [48,56]. We
believe that mammalian TIN2 may be a bifunctional protein
orthologue of fission yeast Poz1 and Ccq1 (discussed later).
While each protein has a distinct role, the overall formation
of the shelterin complex is crucial for telomere maintenance
and telomerase regulation.
Although a shelterin-like protein complex has not been
found, budding yeast has been the best-studied model
system for telomere biology. In this organism, Rap1 directly
binds the telomeric dsDNA and, with its associated proteins
Rif1 and Rif2, negatively controls telomerase action [57,58].
Cdc13 solely binds the telomeric ssDNA to recruit and stabil-
ize telomerase [59–61]. Although these proteins do not
associate to bridge the ds and ss telomeric DNA (figure 1c),
each protein functions to maintain telomere structure and
protect the chromosome ends. Importantly, the mechanisms
and principles of telomeric protein-mediated telomere
homeostasis observed in budding yeast appear to be largely
conserved to fission yeast and mammals (conservation of
the structure and function of telomeres and telomerase has
been reviewed [24,47,62,63]).
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Figure 1. Shelterin conservation at the telomere from yeast to mammals. Schematic diagrams depict the proteins of the shelterin complexes and telomerase
complex in (a) mammalian cells and (b) fission and (c) budding yeasts. Orthologous proteins are shaded in the same colour. Known interactions with the telomerase
complexes and chromatin modifying proteins are indicated. Other interaction proteins are omitted from these diagrams.
rsob.royalsocietypublishing.org
Open
Biol.7:160338
3
 on March 22, 2017http://rsob.royalsocietypublishing.org/Downloaded from 2.2. Telomerase structure and accessory proteins in
fission yeast and mammals
The core components of telomerase comprise the telomerase
RNA (TER1 in fission yeast and TR or TERC in mammals)
and the catalytic reverse transcriptase protein (Trt1 in fission
yeast and TERT in mammals) [64]. The reverse transcriptase
subunit has been well conserved throughout evolution [65].
It can be divided into three major structural and functional
domains: a telomerase essential amino-terminal domain
(TEN), a telomerase RNA-binding domain (TRBD) and a
reverse transcriptase domain (reviewed in [66]). In contrast,
the telomerase RNA varies widely in length and sequence
between different organisms [67–69], and accommodates dis-
tinct RNA recognition proteins. However, some conserved
functional elements exist, including the template domain, a
template boundary element to limit the extent of reverse tran-
scription, and a pseudo-knot domain important for binding
to the telomerase catalytic protein [70]. While these two
core components alone are required for in vitro telomere syn-
thesis [71], the telomerase accessory proteins contribute to the
assembly, stabilization and trafficking of telomerase
(reviewed in [72]).In fission yeast, the Sm family of proteins associate with
the TER1 RNA, contributing to telomerase maturation and
stability. Subsequent replacement of Sm with the Lsm2–8
complex promotes Trt1–TER1 interaction [73]. Est1 directly
binds TER1 and directs telomerase to telomeres through an
interaction between its 14-3-3-like domain and the shelterin
component Ccq1 [74,75].
In mammals, telomerase RNA maturation uses ribosomal
RNA biogenesis (reviewed in [76]). The telomerase RNA,
TERC, is part of a group of RNAs called H/ACA and binds
to a tetrameric complex, composed of the dyskerin, NAF1,
NHP2 and NOP10 proteins [77,78]. This H/ACA ribonucleo-
protein complex stabilizes TERC and ensures the localization
of telomerase to small sub-nuclear organelles called Cajal
bodies where NAF1 is replaced by GAR1 [79–81]. Once
inside the Cajal bodies, TERC associates with TERT to form
the mature telomerase complex. After the assembly of a mini-
mal telomerase complex containing TERT, TR and dyskerin,
interaction with a protein called TCAB1 facilitates trafficking
of telomerase to the telomeres [82].
Mammalian telomerase biogenesis additionally requires
the molecular chaperones heat shock protein 90 (HSP90)
and P23, which bind TERT for assembly with TERC. They
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link to the dynein–dynactin motor, thereby promoting the
transport of hTERT to the nucleus along microtubules [83].
In mammals, the yeast Est1 orthologue, EST1A (SMG6), inter-
acts with TERT and can bind to the telomeric ssDNA [84].
However, Est1A is not directly involved in telomerase recruit-
ment but rather telomere protection and maintenance [85]. It
also plays a role in nonsense mediated-mRNA decay and
appears to affect the abundance of telomeric RNA transcripts
called TERRA [86], which contribute to the regulation of
telomere length homeostasis (reviewed in [87]).Open
Biol.7:1603383. Fundamental mechanisms of telomerase
action in yeasts and mammals
3.1. Telomerase expression and cellular proliferation
The level of functional telomerase enzyme expressed in a
wide range of different cell types has been characterized
using the telomeric repeat amplification protocol assay. This
method essentially allows a measure of the telomerase
activity contained within a cell lysate in vitro [9]. Using this
assay, it has been well documented that most differentiated
somatic cells lack detectable telomerase activity [9,10],
explaining the propensity for telomere shortening through
successive cell divisions [11–13,88].
Telomerase is, however, highly expressed in adult testes
and ovaries, allowing consistently longer telomeres to be
inherited by the next generation [4,13]. Telomerase remains
active during early embryonic development but expression
declines after the blastocyst stage and can no longer be
detected in neonatal somatic cells [4,89,90]. Nevertheless,
most stem cell populations possess weak telomerase activity
[3,5,9,10], which is not sufficient to immortalize cells but
does extend the proliferative ability of these self-renewal
tissues (reviewed in [91,92]). Notably, the Hayflick limit of
somatic cells can be indefinitely evaded when telomere
length is maintained by high ectopic expression of telomerase
[11]. Therefore, the level of telomerase expression defines
telomere length homeostasis and proliferative capacity.
3.2. Common mechanisms for telomerase recruitment
To maintain telomere length homeostasis, active telomerase
needs to be efficiently recruited to every short telomere.
Although telomeric proteins and telomerase components
differ between budding and fission yeasts and mammals,
on-going studies reveal that fundamental common features
operate in telomerase action. In yeasts, telomerase is specifi-
cally recruited to shortened telomeres and the shorter
telomeres are elongated the most during S phase [17]. As
shorter telomeres can accommodate fewer telomeric DNA
binding proteins, a quantitative negative regulation effect is
thought to define the frequency of telomerase recruitment
[93,94]. This system allows telomeric DNA to be retained at
every chromosome end despite the presence of only a few
molecules of active telomerase (figure 2a). This model has
also been indirectly demonstrated in mammals using TERT
heterozygous mouse cells [15].
The mechanism of telomerase recruitment was originally
best defined in budding yeasts. Recruitment of telomerase
during S phase is mediated by association of Est1 and thesingle-stranded telomeric DNA binding protein Cdc13 [95–
99]. This interaction is triggered via phosphorylation of
Cdc13 by the DNA damage response kinases Tel1/Mec1
(ATM/ATR orthologues) and the cell cycle coordinator
Cdk1 [61,99–103]. As mentioned, telomerase recruitment
occurs preferentially at short telomeres owing to a quantitat-
ive negative regulation effect of telomere-bound Rap1 [93,94].
Several studies have shown that recruitment of telomerase
to the telomere in fission yeast occurs via direct interaction of
the telomerase accessory protein Est1 with Ccq1, the telo-
meric Tpz1 (ACD orthologue) binding protein. This occurs
after phosphorylation of Ccq1 by the Rad3 and Tel1 kinases
(ATR and ATM orthologues respectively) [68,69,75,104,105].
However, recent work indicates that the Ccq1–Est1 inter-
action is likely to be transient, as association of Est1 with
TER1 and Ccq1 is mutually exclusive [75,106]. Further
stable association of telomerase at the telomere is achieved
via interactions between Tpz1, Ccq1 and Trt1 [106,107]. The
telomeric dsDNA binding protein Taz1 (TRF1/2 orthologue)
restricts Rad3/Tel1 activation and telomerase recruitment at
the telomere, limiting telomerase recruitment to S phase of
the cell cycle [108,109]. Similar to the quantitative negative
regulation effect observed in budding yeast, Taz1 suppresses
activation of Rad3/Tel1 in a telomere length-dependent
manner. Therefore, Rad3 and telomerase are efficiently
recruited to short telomeres.
Mammalian telomerase recruitment also occurs in S
phase of the cell cycle. The rest of the time it appears to be
concentrated in Cajal bodies or elsewhere in the nucleus
[110,111]. The POT1–ACD complex is known to associate
with telomerase [112–114]. TIN2, the shelterin protein that
bridges TRF1/2 and ACD, is crucial for ACD localization at
telomeres and is also involved in telomerase recruitment
[30,114–116]. Similar to yeasts, phosphorylation of a telo-
meric protein, ACD, occurs during S phase by a kinase,
Cdk1, which is thought to increase the stability of its inter-
action with TERT [117]. However, this phosphorylation-
mediated interaction remains debatable [118]. Therefore,
how the interaction of ACD and telomerase is achieved
remains to be elucidated. It is possible that TIN2 may func-
tion like Ccq1 in fission yeast and initiate the interaction
between ACD and TERT. In support of this hypothesis, the
TIN2-R282H mutation, which is found in patients with dys-
keratosis congenita, impairs telomerase recruitment,
whereas ACD recruitment and shelterin formation are unaf-
fected [116,119]. Another similarity to the yeast recruitment
process is the contribution of ATM/ATR signalling to
telomere elongation. Phosphorylation of the shelterin com-
ponent TRF1 at an ATM/ATR target site (S367) has been
shown to increase telomerase recruitment [120,121]. As
with yeasts, mammalian telomeres are also thought to have
a quantitative negative regulatory effect, with proteins such
as TRF1 and TRF2 negatively regulating telomere extension
by telomerase [122,123]. However, quantification of TRF1
and TRF2 molecules on the telomeres suggests the number
of TRF proteins is limited and long telomeres may not
possess more [124,125]. Indeed, an alternative telomeric
DNA binding protein, TZAP, binds to long telomeres in a
manner that is mutually exclusive to TRF protein binding
[126]. TZAP functions to trim the telomeres by excising the
t-loop, thereby making long telomeres short. As TZAP coun-
teracts the possession of very long telomeres, we anticipate
that it may also function in restricting telomerase activity.
TERT
random target casual interaction
short extension and release
TERT
(b) diffusive telomere length homeostasis?
(a) effective telomere length homeostasis
TERT
TERT
target short telomeres steady interaction
continuous extension
recruitment activation
recruitment activation
Figure 2. Models of telomere maintenance in normal and cancer cells. Schematic diagrams depicting two mode of telomere length homeostasis by distinct tel-
omerase action. In normal cells (a), telomerase is recruited to the shortest telomere and it is extended until it is no longer short. Theoretically, such action would
require a steady interaction between the telomere and telomerase, resulting in continuous extension. In this mode, distribution of telomere length would be the
Gaussian like. In contrast, in cancer cells (b), telomerase recruitment appears to be random as it is independent of telomere length. Furthermore, telomeres are
extended only a small amount, perhaps indicating an inability to maintain a steady interaction with telomerase, resulting in short extension and release. Such casual
interaction permits repetitive recruitment of telomerase to new telomeres. In this mode, distribution of telomere length would be dispersal, resulting in retention of
some short telomeres.
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common fundamental features of telomerase recruitment.
The DNA damage checkpoints appear to monitor and flag
the shorter telomeres that harbour fewer numbers of the
telomere dsDNA binding proteins. In fission yeast and
mammals, a direct interaction between the OB (oligosacchar-
ide/oligonucleotide)-fold domain of Tpz1 and ACD,
especially the so-called TEL patch on the surface [127], and
the TEN domain of the telomerase catalytic subunit is necess-
ary for both telomerase retention and processivity
[106,107,114,128–130]. Notably, mammalian TIN2 and fis-
sion yeast Ccq1, which bind to the C-terminus of ACD and
Tpz1 respectively, are also required for telomerase recruit-
ment, as demonstrated by loss of function mutations
[104,116]. TIN2 and Ccq1 also recruit and associate with the
heterochromatin proteins to control the status of conden-
sation or cohesion at telomeres [131–135]. Owing to the
similarities in function between TIN2 and Ccq1 in terms of
end protection, telomerase recruitment and interaction with
chromatin modifying proteins, it is tempting to speculate
that Ccq1 may be the functional equivalent of mammalian
TIN2. The connection between telomere architecture and tel-
omerase accessibility is slowly being uncovered [30]. Both
fission yeast and mammalian shelterin formation controls
the extendible, non-extendible and extending states [52].
Thus, although the structural similarities of fission yeast
and mammalian shelterin proteins are not great, their
functions and roles are highly conserved.3.3. Current models of telomerase activation
Once telomerase is at the telomere, the single-stranded 30
overhang at the distal end of the telomeric DNA forms the
substrate for telomerase. This anneals with the template
region on the telomerase RNA to form a DNA/RNA
hybrid, and one repeat of telomeric DNA can be added to
the end of the 30 tail using the complementary RNA sequence
as a template. Telomerase then repositions its RNA template
on the 30 end of the substrate and adds another telomeric
repeat. The ability of a single telomerase complex to add mul-
tiple repeats in a single cell cycle without dissociation is
termed repeat addition processivity (RAP) [136,137]. The
exact mechanism by which telomerase can reposition itself
on the template remains to be elucidated. Single molecule
imaging of telomerase revealed that rearrangement of the tel-
omerase RNA molecule is coupled with catalytic action,
posing a possible model for resolution of the DNA/RNA
hybrid and translocation of the RNA template after synthesis
[138]. Thus, it is becoming increasingly clear that multiple
factors affect the processivity or activity (how fast nucleotides
are added) of telomerase after it has been recruited to the
telomere.
In mammals, stable association of telomerase with the
POT1–ACD complex occurs after recruitment to telomeres.
Binding of POT1–ACD to the telomeric ssDNA has been
shown to decrease the rate of RNA primer dissociation, aid
template translocation and enhance telomerase processivity
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the OB fold of ACD, which impair association with TERT,
have been shown to decrease processivity of telomerase by
POT1–ACD in vitro, compared with wild-type ACD
[127,140]. Interestingly, however, another recent study
found that the POT1–ACD complex increases not only telo-
merase processivity but also activity, resulting in more
rapid dissociation from the primer [141]. Thus, ACD-
mediated retention of TERT improves telomerase processivity
and activity.
The TEN domain of mammalian TERT has dual func-
tions. In addition to binding the OB-fold domain of ACD
for telomerase recruitment and RAP stimulation, the TEN
domain supports the stable formation of the RNA–DNA
duplex in the active site of the enzyme [142–144]. The reverse
transcriptase and C-terminal domains of telomerase have also
been proposed to interact with the telomeric DNA substrate
to help promote RAP [145,146]. Thus, while the TEN
domain of TERT associates with ACD for recruitment, it
also promotes stable association of TERT with the telomeric
ssDNA for repeat synthesis. How these two activities of the
TEN domain are coordinated remains to be elucidated.
Recent studies have begun to demonstrate that recruit-
ment of telomerase to the telomere in S/G2 phase does not
equate to activation of the enzyme. In mammals, a residue
within ACD (L104), found on the opposite face of the OB
fold to the TEL patch, has been implicated in regulating telo-
merase activity. Mutation of this residue causes short
telomeres despite the mutant protein binding a similar
amount of telomerase to mutant ACD proteins in cells with
longer telomeres [118,127]. Intriguingly, a mutant form of
the ACD orthologue in fission yeast, Tpz1 (K75A), also
cannot maintain telomere length despite being fully capable
of recruiting telomerase to telomeres [106,107]. Nevertheless,
a stable interaction between Tpz1 and Trt1 is required for the
processive activity of telomerase, as the Tpz1 (K75A)
mutation could be overcome by fusion of Tpz1 directly to
Trt1 [106]. However, telomerase activity requires Ccq1 associ-
ation with the telomerase-bound Tpz1. It has been proposed
that recruitment of telomerase by Ccq1 might temporally and
locally resolve shelterin formation to allow access to the telo-
meric 30 end [52]. Thus, these studies demonstrate that
association of telomerase with telomeres is not sufficient to
regulate telomere length and a subsequent activation step
must exist.
In budding yeast, another telomerase component, Est3,
complexes with Est1 and Est2 at the telomere in S/G2
phase to activate telomerase [96,97,147,148] (figure 1c). Est3
is composed of the OB-fold domain and interacts with the
TEN domain of Est2 with the aid of Est1 [149]. It has been
proposed that the surface residues on Est3 required for telo-
merase activation might be comparable to residue L104 in
ACD [150]. Thus, in all three model organisms, telomerase
activation requires a stable association with the OB-fold
ACD family of proteins as well as conformational changes
in telomere structure to provide telomerase with access to
the ssDNA end.
3.4. Termination of telomerase activity
To understand the processivity of telomerase, we also need to
know how telomerase action is terminated. Several factors at
the telomeres can inhibit, rather than stimulate, telomeraseprocessivity. The CST (CTC1, STN1 and TEN1) complex, of
which homologues for STN1 and TEN1 exist in fission and
budding yeast, is thought to terminate telomere elongation
by recruiting DNA polymerase alpha to the ssDNA over-
hang, thereby displacing telomerase [151–153]. Studies in
budding yeast have shown that Stn1 replaces Est1 as the
Cdc13 binding partner and blocks further telomerase recruit-
ment after S phase [154,155]. However, because telomerase
can repeatedly access the same telomere for further extension
during S phase, we may need to separately consider termin-
ation of processivity and inhibition of telomerase recruitment.
The lack of coupling between telomere extension and tel-
omere lagging strand synthesis may itself lead to inhibition or
termination of telomerase processivity. The presence of a long
G-tail can encourage the formation of certain structural con-
formations in the telomeric DNA, such as G-quadruplexes,
which could potentially inhibit the access of telomerase to
the telomere [32,52,156]. The POT1–ACD complex plays a
role in preventing the formation of such secondary structures
[112,139], as does RPA in fission yeast [157]. As such, the
extent of telomere extension may well be monitored/con-
trolled by the amount of ssDNA binding proteins recruited
to the telomere. Further investigations will be needed to
define these differences and to reveal how telomerase is tem-
porally released from the 30 telomeric overhang to terminate
processivity.4. Telomere biology in cancer
4.1. Unique features of telomerase action in cancer
Telomerase reactivation or upregulation is a critical feature in
the vast majority of cancers. While the mechanisms control-
ling hTERT expression are not fully understood, they are
thought to include hTERT promoter mutations, alterations
in alternative splicing of hTERT pre-mRNA, hTERT gene
amplification, epigenetic changes and disruption of the telo-
mere position effect machinery (reviewed in [158]). Many
studies carried out in human cells in actual fact use estab-
lished cancer cell lines, because primary cells senesce in cell
culture without the induction of telomerase expression. The
characterization of telomeres in cancer cells has revealed
that activated telomerase can largely maintain telomere
length homeostasis as well as cell proliferation. The average
length at which telomeres are maintained directly correlates
with the expression level of telomerase [159–161]. Neverthe-
less, despite the fact that many cancer cells express highly
active telomerase [9,10], their telomeres are shorter than in
paired differentiated normal tissue [162,163]. Strikingly, a
subset of telomeres are left very short (t-stumps) in cancer
cells [14]. Thus, although activated telomerase maintains
chromosome ends overall, the manner in which the telomeres
are maintained appears to differ from that in normal tissue,
such as germ cells.
The reason for the persistent presence of short telomeres
in cancer cells might originate from some modified action
of telomerase. Our understanding of telomerase from studies
in yeasts and murine embryonic stem cells is that it preferen-
tially elongates shorter telomeres until they are no longer
short [15,17]. In contrast, in cancer cells, the majority of telo-
meres are elongated, but they are only extended a short
length [164]. A recent single cell live imaging study using
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dynamic interactions with the majority of telomeres, probing
each chromosome end multiple times during S phase [165].
Thus, we predict that cancer telomerase targets every telo-
mere but only extends them a little (figure 2b). This model
would explain how some telomeres can be left at a short
length or lost but the overall mean telomere length reflects/
correlates with the amount of active telomerase.
Curiously, telomere extension by telomerase is not
coupled with synthesis of the complementary C-rich strand
by polymerase alpha [164], leading to long G-tail extensions
during S phase. It has been proposed that telomerase recruit-
ment/retention (and hence processivity) is terminated by
recruitment of the CST complex, which associates with the
polymerase alpha complex [151,152,166]. However, the prob-
ing interactions described in HeLa cells are only rarely
converted into static interactions long enough to allow telo-
mere elongation [165]. Thus, it is possible that telomerase
might associate with telomeres in an unstable manner in
cancer cells, and therefore it exhibits low processivity and
dissociates before C-strand synthesis.
The hallmark of irregular telomerase action in cancer cells
might also/otherwise stem from the presence of alternatively
spliced hTERT mRNA isoforms. Alternative splicing events
are commonly observed in the majority of cancer cells, and
can both control transcript abundance and contribute to pro-
teome diversity [158]. hTERT mRNA is alternatively spliced
in a wide range of species [167], and a number of variants
are co-expressed at significant levels in tumour and stem
cells [168–170]. However, the regulation and function of
these splice variants is not well understood. Expression of a
major splice variant lacking most of the RT domain has
been correlated with low telomerase activity in cancers
[171,172], and a recent study has shown that the translated
protein product can bind the telomerase RNA and suppress
telomerase activity [173], presumably by competing with
the fully functional hTERT isoform for TERC binding. There-
fore, such deletions or substitutions of other key residues and
domains may well affect the association of telomerase with
shelterin components or the telomeric ssDNA overhang.
The shelterin complex proteins are important not only for
telomerase recruitment but also for control of the DNA
damage response and cell cycle control machineries at telo-
meres. These machineries are impaired or altered in cancer
cells. Several mutations in genes encoding the components
of the shelterin complex have also been identified in cancers.
These mutations might affect telomere status and telomerase
accessibility or processivity. For example, in familial cases of
chronic lymphocytic leukaemia (CLL) loss-of-function
mutations in POT1, affecting either its interaction with the
telomeric ssDNA or with ACD, were found to co-segregate
with CLL [174]. Furthermore, in melanoma patients,
elongated telomeres were associated with mutations that
impair telomeric ssDNA binding and Pot1–ACD–TIN2
interactions [175–178]. Such mutations would impair the
complete formation of the shelterin bridge between the ds
and ss telomeric DNA, disrupting the telomerase non-
extendible state. Finally, in patients with myeloproliferative
neoplasms, significantly reduced telomere length has been
associated with elevated levels of POT1 and TIN2 expression,
and downregulation of ACD and RAP1 compared with
healthy controls [179]. It is not clear whether these alterations
in the genes encoding the shelterin components are a cause ora consequence of the cancers. However, abnormal expression
and/or function of the shelterin proteins is likely to contrib-
ute to telomere dysfunction, thereby driving genetic
aberrations and cancer pathogenesis. At present, the factors
contributing to the hallmarks of telomeres unique to cancer
remain a mystery. However, growing data indicate that
cancer cells may harbour impairments affecting the later
stages of telomerase activity regulation, such as the target-
ing and processivity of telomerase, thereby leaving some
telomeres short.
On top of aberrant telomerase action, overall shortening
of telomeres could be consequences of selection. Random
addition of telomeric repeats should lead to some very long
telomeres. As the amount of telomeric proteins are limited,
insufficient binding of the TRF proteins can cause fragile tel-
omeres and constitutive DNA damage [46]. Hence, cells
containing long telomeres are sensitive to further DNA
damage and could be selectively eliminated by cell death
[180]. Alternatively, homologous recombination or TZAP
may become highly active in cancer cells, thereby actively
trimming long telomeres. Further investigation into the func-
tions of the telomeric proteins and their potential aberrations
in cancer would benefit our understanding of how telomere
homeostasis is differently maintained in cancer cells.4.2. Targeting cancer telomeres and telomerase
Telomerase is an attractive potential drug target in the fight
against cancer owing to its low/absent expression levels in
normal somatic cells and high expression in cancer. Robust
hTERT inhibition can lead to progressive telomere shortening
and eventually cancer cell death. Thus, it should be possible to
target cancer cells reasonably selectively, while the effect on
normal cells should be minimal [181]. Several different com-
pounds that directly target telomerase activity are currently
under development, for example antisense oligonucleotides
such as imetelstat/GRN163L (reviewed in [8]) and small mol-
ecules targeting hTR or hTERT such as BIBR1532 [182].
However, there is a long lag time between administration
and clinical response for therapies that target telomerase
activity, as telomeres must shorten before the effect is seen
[8]. As such, therapies that target the non-canonical functions
of telomerase, or which induce a DNA-damage response
(DDR) at telomeres (i.e. 6-thio-dG, G-quadruplex stabili-
zers and oligonucleotides homologous to the 30 telomeric
overhang) may present a better treatment option [8,183].
Overexpression of an hTERT variant, which lacks most of
the RT domain, was found to confer cells with a protective
advantage against cisplatin-induced apoptosis, indicating a
telomere homeostasis independent role for hTERT in cancer
pathophysiology [173]. Thus, elucidating the connection
between telomerase regulation and the regulation of RNA
splicing has a great deal of potential to provide new insights
into cancer biology [8]. Similarly, inhibition of the functions
of the shelterin proteins could present a viable therapeutic
option. For example, TRF1 is overexpressed in many types
of cancer and plays an important role in telomeric DNA repli-
cation. Loss of TRF1 leads to uncapping of telomeres
regardless of telomere length, and has been shown to
impair lung tumour growth in mouse models [184]. How-
ever, it is not clear what effects targeting the shelterin
proteins would have on normal cells.
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upregulation of tRNAs [185] and WNT/b-catenin signalling
[186] by interacting with their promoter regions. This non-
canonical function of TERT appears to be TERC and RT
activity-independent. Such aberrant transcription owing to
TERT reactivation contributes to carcinogenesis. Therefore,
inhibitors against multifunctional tankyrase, which is
involved in telomere homeostasis, mitotic spindle formation
and WNT/b-catenin signalling, and HSP90, which is
involved in signal transduction, intracellular transport and
protein degradation, have been explored to selectively kill
cancer cells [183]. Finally, a number of immunotherapies
are being tested in clinical trials, which aim to sensitize the
immune system to tumour cells expressing protein fragments
or peptides of telomerase on their cell surface. These are
among the most promising telomerase targeting therapeutics,
with hTERT specific immune responses being seen in telo-
merase positive tumours, minimal effects in normal cells
and no autoimmunity (reviewed in [8]). Thus, there is a lot
of potential in anti-telomerase therapeutics for cancer treat-
ment, and a greater understanding of the regulation of
telomerase expression, functions and activity can only serve
to further enlighten the search for safe and effective
treatments.5. Conclusions and future perspectives
Until fairly recently, the activity of telomerase was thought to
be controlled by limiting access to the telomeres. However,
the collective data illustrate that telomerase recruitment and
activation are separate events. Such a two-step mechanism
is likely to be conserved from yeast to humans. However,
the structural biology and biochemistry underlying the pro-
cess of telomerase activation remains largely unknown and
presents an important area for future research. In many
human cancer cells, telomerase is highly expressed and
recruited indiscriminately to all telomeres. Nevertheless, pro-
cessivity is low, resulting in the maintenance of shorttelomeres. As such, both the preferential targeting of short
telomeres and the processivity/activity of telomerase may
be altered in cancer cells. We believe that t-stumps and
altered telomerase regulation, such unique feature of telo-
meres in cancer, would be an ideal target for cancer
therapeutics. Further investigation of telomerase regulation
and action would benefit our understanding of the differ-
ences in telomere homeostasis between cancer and normal
cells, and hopefully lead to the development of effective
and safe anti-cancer treatments.6. Take home messages
— Telomere function and action of telomerase are largely
conserved between yeasts and mammals.
— The structural biology and biochemistry underlying the
process of telomerase activation remains largely
unknown, but emerging studies indicate evolutionary
conservation of the mechanisms of telomere homeostasis
from yeast to mammals.
— Telomere homeostasis differs between normal cells and
cancer cells.
— The maintenance of short telomeres in cancer cells is
thought to predispose to genomic instability, and indi-
cates that the targeting and processivity of telomerase
may be impaired in cancer.
— Telomeres and telomerase are attractive targets for anti-
cancer therapeutics owing to its uniqueness in cancer
cells, allowing selective targeting of cancer cells whilst
having minimal effects on normal tissue.
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